Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 16506-27-7 Chemical Structure| 16506-27-7

Structure of Bendamustine
CAS No.: 16506-27-7

Chemical Structure| 16506-27-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bendamustine is a DNA cross-linking agent.

Synonyms: SDX-105 free base

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bendamustine

CAS No. :16506-27-7
Formula : C16H21Cl2N3O2
M.W : 358.26
SMILES Code : O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
Synonyms :
SDX-105 free base
MDL No. :MFCD00866481
InChI Key :YTKUWDBFDASYHO-UHFFFAOYSA-N
Pubchem ID :65628

Safety of Bendamustine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H311-H331-H341
Precautionary Statements:P201-P202-P261-P264-P270-P271-P280-P302+P352-P304+P340-P308+P313-P310-P330-P361-P403+P233-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Bendamustine

DNA

Isoform Comparison

Biological Activity

Description
Bendamustine (SDX-105 free base), a purine analogue, acts as a DNA cross-linking agent, activating DNA-damage stress response and apoptosis. It possesses potent alkylating, anticancer, and antimetabolite properties [1].
Target
  • DNA synthesis

In Vitro:

Cell Line
Concentration Treated Time Description References
U251MG 5.5-65.3 μM BDM retains its cytotoxic activity against both MGMT negative and TMZ-resistant cell lines PMC5830080
HEK293T cells 20, 10, 5 µM 48 hours Detect the transcriptional activation effect of VDR on the CYP24A1 promoter PMC5477689
THP-1 cells 100 µM 2 hours Validate the binding of Vitexin to VDR protein through CETSA and DARTS experiments PMC5477689
U87MG 5.5-65.3 μM BDM retains its cytotoxic activity against both MGMT negative and TMZ-resistant cell lines PMC5830080
T98G 5.5-65.3 μM BDM retains its cytotoxic activity against both MGMT negative and TMZ-resistant cell lines PMC5830080
KARPAS-422 200 µM 1.5 days To evaluate the cytotoxicity of Bendamustine on DLBCL cells, results showed significant inhibition of cell viability. PMC11551994
SU-DHL2 200 µM 1.5 days To evaluate the cytotoxicity of Bendamustine on DLBCL cells, results showed significant inhibition of cell viability. PMC11551994
OCI-LY1 200 µM 1.5 days To evaluate the cytotoxicity of Bendamustine on DLBCL cells, results showed significant inhibition of cell viability. PMC11551994
CLL-B cells 0.1, 30, 90 μM 48 hours Evaluated cytotoxic effects of bendamustine combined with m15-IgG1 antibody, showing synergistic effects in both high- and low-risk CLL patients. PMC5438492

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice MCL xenografts Intraperitoneal injection 0.5 mg Two subsequent days every two weeks (2 cycles) Anti-tumor activity remained comparable between JEKO-1 R clone and JEKO-1 CTRL-xenografted mice NL-101
SCID beige mice JVM-13 leukemia xenograft model Intraperitoneal injection 30 mg/kg Administered on days 19 and 20, followed by another 2-day cycle 28 days later Assessed antitumor efficacy of bendamustine alone and in combination with PF-06747143, with the combination group showing enhanced tumor burden reduction and survival benefit. NL-101
SCID or SCID-bg mice Xenograft models of non-Hodgkin’s lymphoma Intravenous injection 25 mg/kg Single dose To evaluate the efficacy of Bendamustine alone or in combination with rituximab in non-Hodgkin’s lymphoma models. Results showed that Bendamustine exhibited significant activity in all tested tumor models, with enhanced effects when combined with rituximab. PMC3575786

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01570049 Non-Hodgkin Lymphoma by Clinic... More >>al Course Less << PHASE3 UNKNOWN 2025-12-12 Tianjin Medical University Can... More >>cer Institute and Hospital, Tianjin, Tianjin, 300060, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China Less <<
NCT01929265 Indolent Non-follicular|Non-Ho... More >>dgkin's Lymphoma Less << PHASE2 COMPLETED 2025-05-15 SC Ematologia - AO SS. Antonio... More >> e Biagio e C. Arrigo, Alessandria, AL, 15121, Italy|SC Ematologia Spedali Civili, Brescia, BS, Italy|Divisione di Ematologia e Trapianti, Ospedale San Maurizio, Bolzano, BZ, Italy|Divisione di Ematologia, Centro Trapianto di Cellule Staminali, San Giovanni Rotondo, Foggia, Italy|Divisione Ematologia I , Ospedale San Martino, Genova, GE, Italy|S.C. Ematologia Azienda Ospedaliera Papardo, Messina, ME, Italy|Divisione di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas, Rozzano, Milano, Italy|Divisione di Ematologia Ospedale Niguarda, Milano, MI, Italy|Centro Oncologico Modenese, Modena, MO, Italy|Ematologia Azienda Ospedaliero Universitaria Paolo Giaccone, Palermo, PA, Italy|Div. Oncologia Medica - CRO, Centro di Riferimento Oncologico, Aviano, PN, Italy|UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Oncoematologia Istituto Pascale, Napoli, Italy|S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore, Novara, Italy|UO Ematologia Università - Policlinico San Matteo, Pavia, Italy|Ematologia Ospedale Santo Spirito, Pescara, Italy|UOA Ematologia, Ospedale Civile Ospedale G. da Saliceto, Piacenza, Italy|Div. Ematologia AO Bianchi Melacrino Morelli, Reggio Calabria, Italy|Ematologia, Azienda Ospedaliera Arcispedale "S.Maria Nuova", Reggio Emilia, Italy|Ematologia, Università "La Sapienza", Roma, Italy|Clinica Ematologia Policlino Le Scotte, Siena, Italy|Struttura Complessa di Onco-Ematologia Azienda Ospedaliera S.Maria, Terni, Italy|SC Ematologia - Città della Salute e della Scienza, Torino, Italy|SC Ematologia U - Città della Salute e della Scienza, Torino, Italy|Clinica Ematologica e Unità di Terapie Cellulari 'Carlo Melzi' AOU S. Maria della Misericordia, Udine, Italy Less <<
NCT00661739 Metastatic Breast Cancer PHASE1 COMPLETED 2025-05-11 -
NCT01701076 Multiple Myeloma PHASE2 COMPLETED 2025-02-16 Kantonsspital St. Gallen, St. ... More >>Gallen, 9000, Switzerland Less <<
NCT02315157 Multiple Myeloma|Plasma Cell L... More >>eukemia Less << PHASE1 WITHDRAWN - Thomas Jefferson University, P... More >>hiladelphia, Pennsylvania, 19107, United States Less <<
NCT05006469 Bendamustine|Multiple Myeloma PHASE3 UNKNOWN 2024-05-31 Shengjing Hospital of China Me... More >>dical University, Shenyang, Liaoning, 110000, China Less <<
NCT00879073 Brain Metastases PHASE1 TERMINATED 2025-12-12 H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States Less <<
NCT00959686 T-cell Lymphoma PHASE2 COMPLETED 2025-02-13 Dr Gandhi DAMAJ, Amiens, 80054... More >>, France Less <<
NCT03315520 Relapsed/Refractory Malignant ... More >>Lymphomas Less << PHASE2 UNKNOWN 2020-12-31 The Federal Budget-Funded Inst... More >>itution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, 105203, Russian Federation Less <<
NCT00790855 Acute Myeloid Leukemia|Myelody... More >>splastic Syndrome|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia Less << PHASE1|PHASE2 TERMINATED 2025-03-12 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT01484626 Multiple Myeloma PHASE1|PHASE2 TERMINATED 2014-06-18 Loyola University Medical Cent... More >>er, Maywood, Illinois, 60153, United States Less <<
NCT04127916 Mantle Cell Lymphoma UNKNOWN 2020-12-31 Samsung Medical Center, 81 Irw... More >>on-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, 06351, Korea, Republic of|Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, 06351, Korea, Republic of Less <<
NCT01088984 Leukemia PHASE1|PHASE2 COMPLETED 2025-08-11 Teva Investigational Site 17, ... More >>Orange, California, United States|Teva Investigational Site 12, San Diego, California, United States|Teva Investigational Site 10, St. Petersburg, Florida, United States|Teva Investigational Site 8, Baltimore, Maryland, United States|Teva Investigational Site 16, Boston, Massachusetts, United States|Teva Investigational Site 9, Detroit, Michigan, United States|Teva Investigational Site 1, Jackson, Mississippi, United States|Teva Investigational Site 5, Kansas City, Missouri, United States|Teva Investigational Site 14, St. Louis, Missouri, United States|Teva Investigational Site 15, New York, New York, United States|Teva Investigational Site 18, Portland, Oregon, United States|Teva Investigational Site 11, Hershey, Pennsylvania, United States|Teva Investigational Site 7, Philadelphia, Pennsylvania, United States|Teva Investigational Site 19, Memphis, Tennessee, United States|Teva Investigational Site 3, Dallas, Texas, United States|Teva Investigational Site 4, Fort Worth, Texas, United States|Teva Investigational Site 13, Houston, Texas, United States|Teva Investigational Site 2, Seattle, Washington, United States|Teva Investigational Site 6, Milwaukee, Wisconsin, United States|Teva Investigational Site 300, Herston, Australia|Teva Investigational Site 301, Parkville, Australia|Teva Investigational Site 302, Randwick, Australia|Teva Investigational Site 520, Minsk, Belarus|Teva Investigational Site 615, Barretos-SP, Brazil|Teva Investigational Site 616, Caxias do Sul, Brazil|Teva Investigational Site 613, Curitiba-PR, Brazil|Teva Investigational Site 612, Porto Alegre, Brazil|Teva Investigational Site 614, Porto Alegre, Brazil|Teva Investigational Site 617, Sao Paulo-SP, Brazil|Teva Investigational Site 610, Sao Paulo, Brazil|Teva Investigational Site 611, Sao Paulo, Brazil|Teva Investigational Site 100, Toronto, Canada|Teva Investigational Site 501, Jerusalem, Israel|Teva Investigational Site 503, Petach Tikva, Israel|Teva Investigational Site 502, Ramat Gan, Israel|Teva Investigational Site 330, Seoul, Korea, Republic of|Teva Investigational Site 331, Seoul, Korea, Republic of|Teva Investigational Site 332, Seoul, Korea, Republic of|Teva Investigational Site 333, Seoul, Korea, Republic of|Teva Investigational Site 603, Guadalajara, Mexico|Teva Investigational Site 600, Mexico City, Mexico|Teva Investigational Site 601, Mexico City, Mexico|Teva Investigational Site 602, Monterrey, Mexico|Teva Investigational Site 303, Auckland, New Zealand|Teva Investigational Site 531, Bialystok, Poland|Teva Investigational Site 530, Lublin, Poland|Teva Investigational Site 532, Warszawa, Poland|Teva Investigational Site 511, Moscow, Russian Federation|Teva Investigational Site 510, St. Petersburg, Russian Federation|Teva Investigational Site 320, Singapore, Singapore Less <<
NCT01649622 Leukemia|Lymphoma PHASE2 WITHDRAWN - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.79mL

0.56mL

0.28mL

13.96mL

2.79mL

1.40mL

27.91mL

5.58mL

2.79mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories